DIRS.INFO The most relevant business & tech news

☆ Family of Henrietta Lacks finally settles lawsuit against biotech company accused of profiting billions of dollars from collecting the Black woman's cancer cells without her consent
▼ + stars: | 2023-08-01 | by ( Lea Skene | Sarah Brumfield | Associated Press | ) www.businessinsider.com time to read: +6 min

Henrietta Lacks changed modern medicine when doctors took her cells without her consent in 1951. Despite that incalculable impact, the Lacks family had never been compensated. Henrietta Lacks' cells have been part of many medical breakthroughs. "The exploitation of Henrietta Lacks represents the unfortunately common struggle experienced by Black people throughout history," the complaint reads. "It was a long fight — over 70 years — and Henrietta Lacks gets her day."

Persons: Henrietta, HeLa, Ben Crump, Crump, didn't, Rebecca Skloot, Oprah Winfrey, Johns Hopkins, Fisher, George Floyd's, Alfred, Carter Jr, Chris Van Hollen, Ben Cardin, Van Hollen Organizations: Service, Johns Hopkins Hospital, Fisher Scientific Inc, Associated Press, HBO, Johns Hopkins Medicine, Maryland Democrats Locations: Wall, Silicon, Waltham , Massachusetts, Baltimore, Virginia, United States, Baltimore's

The buyout consortium has turned to other private equity firms to help fund the deal as direct lenders, one of the sources added. There is no certainty that Warburg Pincus and Advent will successfully complete negotiations to acquire the unit and Baxter may still opt to sell to another bidder or keep the business, according to the sources. Baxter, Warburg and Advent did not immediately respond to requests for comment. Baxter's biopharma solutions unit supports drugmakers in the formulation, development and commercialization of drugs typically given by infusion or injection, such as biologics and vaccines. The company said dialysis operations, which are a part of Baxter's renal care unit, had become a drag on its margin.

March 20 (Reuters) - U.S. scientific instruments maker Thermo Fisher Scientific Inc (TMO.N) and South Korea's Celltrion Inc (068270.KS) are among those competing to acquire the biopharma solutions business of medical device maker Baxter International Inc (BAX.N), according to people familiar with the matter. Baxter, which has a market value of $19 billion, had total debt of $16.6 billion as of the end of December. Private equity firms, including KKR & Co (KKR.N) and Carlyle Group (CG.O), have also expressed interest in the Baxter business, the sources said. Baxter said in January it was exploring alternatives for its biopharma solutions business and would also spin off its kidney care units. Baxter's biopharma solutions unit supports drugmakers in the formulation, development and commercialization of drugs typically given by infusion or injection, such as biologics and vaccines.

Reuters reported in March 2020 that Syneos was working with investment bank Centerview Partners LLC to explore a sale. Syneos, which has a market capitalization of $3.9 billion and carries a $2.9 billion debt pile, was not immediately available for comment. Based in Morrisville, North Carolina, Syneos helps pharmaceutical companies with clinical trials and to market their drugs. There has been a wave of consolidation among contract research organizations in a bid to lower costs, amass more clinical trial data and win customers. Labcorp (LH.N), for example, said earlier this month that it will complete the spinoff of its contract research organization, called Fortrea, by the middle of this year.

☆ Illumina Makes Its Interim CFO Permanent
▼ + stars: | 2023-02-01 | by ( Kristin Broughton | ) www.wsj.com time to read: +3 min

Gene-sequencing company Illumina Inc. on Wednesday named Joydeep Goswami as chief financial officer, giving its interim CFO the role on a permanent basis. Mr. Goswami joined Illumina in 2019 as chief strategy and corporate development officer, overseeing strategic partnerships and acquisitions. Illumina CFO Joydeep Goswami. He added that he received a crash course in traditional areas of finance, including treasury, tax and audit, while serving as interim CFO. As CFO, Mr. Goswami plans to keep Illumina’s spending on innovation roughly constant as a percentage of revenue.

"The jury is still out," on which technology will dominate, said Dr. Sadik Esener, director of the Cancer Early Detection Advanced Research Center at the OHSU Knight Cancer Institute in Portland, Oregon. He added it could take as long as 20 years to show that an early cancer detection test saved lives. If proven to work, early cancer detection tests could help doctors identify cancer risk in patients long before symptoms or other indicators develop. DIFFERENT APPROACHESSeveral of the leading contenders take vastly different approaches to cancer detection and it is not yet clear which methods will prove most useful or when. Some are working on blood tests to detect different markers of early cancer, including proteins.

☆ Thermo Fisher to buy diagnostics firm Binding Site for $2.6 bln
▼ + stars: | 2022-10-31 | by ( ) www.reuters.com time to read: 1 min

Oct 31 (Reuters) - Thermo Fisher Scientific Inc (TMO.N) said on Monday it would buy specialty diagnostics firm the Binding Site Group from a group led by European private equity firm Nordic Capital in an all-cash transaction valued at 2.25 billion pounds ($2.6 billion). The Birmingham-based company's test helps detect and monitor multiple myeloma, a cancer in a type of white blood cell, and is on track to deliver more than $220 million of revenue in 2022, Thermo Fisher said. Thermo Fisher, which makes scientific instruments, expects the transaction to be completed in the first half of 2023 and boost adjusted earnings per share by 7 cents on the first full-year of ownership. Reporting by Leroy Leo and Pratik Jain in Bengaluru; Editing by Sriraj KalluvilaOur Standards: The Thomson Reuters Trust Principles.

Search resuls for: "Fisher Scientific Inc"

7 mentions found